Mode
Text Size
Log in / Sign up

High-dose omega-3 PUFA and EPA significantly reduce risk of asthma and wheezing in childrenHigh dose omega-3 fatty acids may lower asthma risk in children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider high-dose omega-3 PUFA (greater than or equal to 1,200 mg/day) or EPA for risk reduction in pediatric asthma.

This meta-analysis evaluated the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) and high-dose eicosapentaenoic acid (EPA) on the risk of asthma and wheezing in a population of 4156 children. The analysis sought to determine if these supplements provide protective effects against respiratory symptoms.

The study found no overall association between general omega-3 PUFA intake and asthma risk (OR: 1.00; 95% CI: 0.84-1.18). However, specific high-dose regimens showed significant benefits. High-dose omega-3 PUFA (greater than or equal to 1,200 mg/day) was associated with a significantly decreased risk (OR: 0.66; 95% CI: 0.46-0.94). Similarly, high-dose EPA (greater than or equal to 1,000 mg/day) showed a significant reduction in risk (OR: 0.67; 95% CI: 0.46-0.97).

A dose-response analysis revealed a linear relationship where every 1,000 mg/day increase resulted in a 26.6% reduction in risk (OR: 0.734; p=0.002; 95% CI: 0.602-0.896). The authors note that while high-dose regimens, particularly those involving EPA, provide substantial protection, further validation is required to confirm these findings in clinical practice.

How this fits prior evidence

This meta-analysis addresses a gap in identifying specific nutritional interventions for pediatric respiratory health. While previous evidence identified the CXCL16/CXCR6 axis as a bidirectional regulator in inflammatory diseases like asthma and noted that IL-33 and TSLP are key targets in T2 asthma pathogenesis, this study provides specific data on high-dose omega-3 PUFA and EPA as protective factors against asthma and wheezing.

Managing childhood asthma can be a constant worry for parents. A large review of clinical trials involving over 4,000 children looked at whether omega-3 polyunsaturated fatty acids (omega-3 PUFA) could help lower the risk of asthma and wheezing.

The findings show that while general omega-3 intake didn't show a broad effect, specific high doses did make a difference. Children taking 1,200 mg or more of omega-3 per day saw a significant decrease in asthma risk. Similarly, children taking high doses of eicosapentaenoic acid (EPA), a specific type of omega-3, at 1,000 mg or more daily also showed a reduced risk.

Researchers found a clear link between the amount taken and the level of protection. For every 1,000 mg increase in daily intake, there was about a 26.6% reduction in asthma risk. While these results are promising for high-dose regimens, experts note that more studies are needed to fully confirm these findings.

What this means for you:
High doses of omega-3 and EPA may significantly lower the risk of asthma and wheezing in children.

Common questions

Does any amount of omega-3 help with childhood asthma?

Not necessarily. The study found no overall association between general omega-3 intake and asthma risk. However, specific high doses—at least 1,200 mg of omega-3 or 1,000 mg of EPA daily—showed a significant reduction in the risk of asthma and wheezing for children.

How does the amount of omega-3 affect the results?

There is a clear dose-response relationship. For every 1,000 mg increase in daily intake, there was a 26.6% reduction in the risk of asthma and wheezing. This suggests that higher doses provide more protection than lower amounts.

Is this finding certain enough to change treatment?

The results are promising for high-dose regimens, especially those involving EPA. However, because the study is a meta-analysis of existing trials, researchers note that further validation is required before these findings can be fully confirmed.

Study Details

Study typeMeta analysis
Sample sizen = 4,156
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND AND OBJECTIVES: Asthma, a chronic inflammatory airway disease characterized by wheezing, imposes a substantial global health burden on children. Given the potential of early-life omega-3 polyunsaturated fatty acid (omega-3 PUFA) supplementation as an anti-inflammatory intervention to prevent childhood asthma and wheezing, this meta-analysis aims to clarify its efficacy and investigate dose-dependency. METHODS AND STUDY DESIGN: This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Three reviewers independently evaluated the studies, extracted data, and assessed bias using the Jadad scale. The outcomes included the risk of asthma/wheezing: pooled odds ratios (ORs) were calculated using fixed-effects models, along with sensitivity/subgroup analyses and dose-response meta-regression. RESULTS: Twelve randomized controlled trials (RCTs) involving 4,156 participants showed no overall association between omega-3 PUFA and a reduced risk of asthma/wheezing (odds ratio [OR]: 1.00; 95% confidence interval [CI]: 0.84-1.18). However, high-dose supplementation (≥1,200 mg/day) significantly decreased the risk (OR: 0.66; 95% CI: 0.46-0.94). Similarly, high-dose eicosapentaenoic acid (EPA≥1,000 mg/day) also significantly reduced the risk (OR: 0.67; 95% CI: 0.46-0.97). Dose-response analysis confirmed a linear relationship (p=0.002), indicating a 26.6% reduction in risk for every 1,000 mg/day increase in dose (OR: 0.734; 95% CI: 0.602-0.896). Subgroup analyses revealed no heterogeneity with respect to study location, allergy risk, or follow-up duration. CONCLUSIONS: Early-life omega-3 PUFA supplementation reduces childhood asthma/wheezing risk in a dose-dependent manner. High-dose regimens, particularly those involving EPA, provide substantial protection, suggesting a potential clinical strategy for prevention, although further validation is required.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.